$3.05 10.8%
ALLO Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Allogene Therapeutics

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer.

Allogene Therapeutics
Price $3.05
Target Price Sign up
Volume 4,730,000
Market Cap $731M
Year Range $2.08 - $5.63
Dividend Yield 0%
Revenue per Employee $66,177
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2422,00017M-17M-65M0-0.380
Q4 '2323M37M-15M-86M-68M-0.510
Q3 '2343,00017M-17M-62M-59M-0.370
Q2 '2344,00019M-18M-79M-77M-0.530
Q1 '2352,00019M-19M-100M-99M-0.680

Insider Transactions View All

MESSEMER DEBORAH M. filed to sell 166,765 shares at $2.3.
June 20 '24
Humer Franz B filed to sell 255,253 shares at $2.3.
June 3 '24
Belldegrun Arie filed to buy 1,724,137 shares at $2.9.
May 20 '24
Parker Geoffrey M. filed to buy 819,590 shares at $3.6.
March 6 '24
MESSEMER DEBORAH M. filed to sell 62,456 shares at $2.7.
December 20 '23

What is the Market Cap of Allogene Therapeutics?

The Market Cap of Allogene Therapeutics is $731M.

How Many People Work at Allogene Therapeutics?

As of our latest update, Allogene Therapeutics employed approximately 344 people worldwide. However, it's important to note that Allogene Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Allogene Therapeutics' revenue per employee?

$66,177. To calculate Allogene Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Allogene Therapeutics?

Currently, the price of one share of Allogene Therapeutics stock is $3.05.

How can I analyze the ALLO stock price chart for investment decisions?

The ALLO stock price chart above provides a comprehensive visual representation of Allogene Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Allogene Therapeutics shares. Our platform offers an up-to-date ALLO stock price chart, along with technical data analysis and alternative data insights.

Does ALLO offer dividends to its shareholders?

As of our latest update, Allogene Therapeutics (ALLO) does not offer dividends to its shareholders. Investors interested in Allogene Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Allogene Therapeutics?

Some of the similar stocks of Allogene Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.